We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
Notice for olaparib (AstraZeneca Pty Ltd)
Active ingredients
olaparib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the maintenance treatment of patients with newly diagnosed BRCA-mutated advanced ovarian cancer.
Therapeutic area
Oncology